A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study von Fountzilas, G., Athanassiades, A., Giannakakis, T., Briasoulis, E., Bafaloukos, D., Kalogera-Fountzila, A., Onienaoum, A., Kalofonos, H., Pectasides, D., Andreopoulou, E., Bamia, C., Kosmidis, P., Pavlidis, N., Skarlos, D.

Volltext